The National Institutes of Health's restrictions on research partnerships with foreign institutions have affected one in four U.S. scientists, including those working on critical medical advancements like Duchenne muscular dystrophy treatments. This impacts developers and tech professionals by limiting collaborative opportunities that are crucial for advancing biomedical research. The ongoing implementation of these restrictions will likely continue to shape future research strategies and international collaborations.
Read the full article at STAT News
Want to create content about this topic? Use Nemati AI tools to generate articles, social posts, and more.



